I. GENERAL INFORMATION:

NADA	128-620
Sponsor:	Hoechst-Roussel Agri-Vet Company Route 202-206 P. O. Box 2500 Somerville, New Jersey 08876-1258
Generic Name:	Fenbendazole
Trade Name:	PANACUR ®
Marketing Status:	Rx
Effect of Supplement:	This supplement provides for an expanded use of fenbendazole in a new species (goats).

III. INDICATIONS FOR USE

For the removal and control of stomach and intestinal worms, Haemonchus contortus and Ostertagia circumcincta, in goats.

III. DOSAGE

A.	DOSAGE FORM	Fenbendazole 10% suspension will be marketed as an oral anthelmintic in 1000 mL multidose glass bottle.
B.	ROUTE OF ADMINISTRATION	orally
C.	RECOMMENDED DOSAGES:	a single dosage of 5 mg fenbendazole per kg of body weight.

IV. EFFECTIVENESS

This has been addressed in PMF 5118, 56 FR 13650, April 3, 1991.

V. ANIMAL SAFETY

This has been addressed in PMF 5118, 56 FR 13650, April 3, 1991.

VI. HUMAN FOOD SAFETY

a. Toxicity Studies - These have been adequately addressed in the original approval.

b. Tolerance for Residues - A tolerance of 0.8 ppm is established for parent fenbendazole in liver of goats.

c. Metabolism and Total Residue Depletion Studies - Adequate data on metabolism have been submitted for cattle under approved NADA 128-620 and no unique metabolites of toxicological concern are anticipated to result from the recommended use of fenbendazole in goats.

d. Withdrawal Time - Residue depletion data submitted under PMF 5118, 56 FR 13650, April 3, 1991, support a 6-day preslaughter withdrawal time for goats treated with the recommended dose of fenbendazole 10% suspension.

VII. AGENCY CONCLUSIONS

The data submitted in support of this supplemental NADA satisfy the requirements of Section 512 of the Food, Drug, and Cosmetic Act and 21 CFR 514.106 of the implementing regulations. The data demonstrate that fenbendazole 10% suspension Panacur ® is safe and effective, when used in accordance with labeling directions, for the removal and control of stomach and intestinal worms, Haemonchus contortus and Ostertagia circumcincta, in goats.

The human food safety data submitted under PMF 5118, 56 FR 13650, April 3, 1991, indicate that the goats treated with fenbendazole at the recommended dosage will require 6 days for the depletion of fenbendazole residue from the edible tissues.

The agency concludes that appropriate directions for use have been written for prescription use of this oral suspension drug in goats. The currently approved fenbendazole suspension is codified in Section 21 CFR 520.905a for use in cattle.

The agency has carefully considered the potential environment effects of this action and has concluded that the action will not have a significant impact on the human environment and that an environmental impact statement is not required. The agency's finding of no significant impact (FONSI) and the evidence supporting that finding are contained in an environmental assessment which may be seen in the Dockets Management Branch (HFA 305), Park Building (Room 1-23), 12420 Parklawn Drive, Rockville, MD 20855.

Under the agency's supplemental approval policy, 21 CFR 514.106(b)(2)(vii), this is a Category II change that did not require a reevaluation of the safety and effectiveness data contained in the Public Master File (PMF) 5118.

Under Section 512(c)(2)(F)(iii) of the Federal Food, Drug, and Cosmetic Act, this approval does not qualify for marketing exclusivity because no new clinical or field investigations (other than bioequivalence or residue studies) and no new human food safety studies (other than bioequivalence or residue studies) essential to the approval of the supplement were conducted or sponsored by the applicant.

VIII. LABELING (Attached)

1. PMF 5118 Labeling for Panacur(R) 10% suspension

Copies of these labels may be obtained by writing to the:

Food and Drug Administration
Freedom of Information Staff (HFI-35)
5600 Fishers Lane
Rockville, MD 20857

Or requests may be sent via fax to: (301) 443-1726. If there are problems sending a fax, call (301) 443-2414.